TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Psychopharmacology of Psilocybin in Cancer Patients
Brief Summary: This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices.


Options:
A: GRID-HAM-D-17 -- Structured Interview Guide for the Hamilton Depression Scale. (Baseline, 5 weeks post session 1 and 2, 6-month follow-up); HAM-A Assessed With the SIGH-A -- a Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A). (Baseline, 5 weeks post session 1 and 2, 6-month follow-up)
B: HADS Anxiety (2-4 weeks prior to drug administration); HADS Anxiety (1 day prior to drug administration 1); HADS Anxiety (1 day post drug administration 1); HADS Anxiety (6 weeks post drug administration 1); HADS Anxiety (1 day prior to drug administration 2); HADS Anxiety (6 weeks post drug administration 2); HADS Anxiety (26 weeks post drug administration 2); State-Trait Anxiety Inventory (STAI) State (2-4 weeks prior to drug administration/ Baseline); STAI State (1 day prior to drug administration 1); STAI State (1 day post drug administration 1); HADS Depression (2-4 weeks prior to drug administration/ Baseline); STAI State (6 weeks post drug administration 1); STAI State (1 day prior to drug administration 2); STAI State (1 day post drug administration 2); STAI State (6 weeks post drug administration 2); STAI State (26 weeks post drug administration 2); STAI Trait (2-4 weeks prior to drug administration/ Baseline); STAI Trait (1 day prior to drug administration 1); STAI Trait (1 day post drug administration 1); STAI Trait (6 weeks post drug administration 1); STAI Trait (1 day prior to drug administration 2); STAI Trait (1 day post drug administration 2); STAI Trait (6 weeks prior to drug administration 2); STAI Trait (6 weeks post drug administration 2); HADS Depression (1 day prior to drug administration 1); HADS Depression (1 day post drug administration 1); HADS Depression (6 weeks post drug administration 1); HADS Anxiety (1 day post drug administration 2); HADS Depression (1 day post drug administration 2); HADS Depression (6 weeks post drug administration 2); HADS Depression (26 weeks post drug administration 2)
C: depressive symptoms (3 to 28 days)
D: Hot Flash Symptom Severity Score (12 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Pilot Tolerance and Bone Status of Healthy, Term Infants Fed Infant Formulas
Brief Summary: To compare the tolerance and early bone status of healthy, term infants fed formulas during the first three months of life.


Options:
A: Mean rank stool consistency at 14 days of age (14 days of age)
B: Weight Gain Velocity (up to 24 weeks)
C: Composite measure of Growth (1 year)
D: Infant weight gain (Between ages 14 weeks (+/- 1 week) and 12 months (+/- 2 weeks))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Reduced in-Hospital Mortality After Improved Management of Patients Hospitalised With Malaria. A Randomised Trial
Brief Summary: The study intend to evaluate whether the use of standardised malaria case management protocol plus financial incentives added to the availability of free drugs reduce the case-fatality at the paediatric ward.


Options:
A: Number of Participants Who Present Children for HIV Testing (2 months); Number of Days Participants Take to Bring Children for HIV Testing (2 months)
B: HIV viral suppression at 6 months (6 months)
C: Receipt of two or more home visits from an FLW in the final trimester of pregnancy and delivery at a facility (versus home birth), using maternal survey response (2 year follow-up); Receipt of any postnatal home visits from an FLW (in the first 24 hours at home after delivery and in first month following delivery), using maternal survey response (2 year follow-up); Any complementary feeding of solid or semisolid food for infants aged 6-11 months, using maternal survey response (2 year follow-up); Immunizations (2 year follow-up); Receipt of iron-folic acid tablets by month 4 and consumption of at least 90 tablets, using maternal survey response (2 year follow-up); Clean Cord Care (2 year follow-up); Kangaroo Mother Care (skin to skin care) (2 year follow-up); Delayed Bath (2 year follow-up); Initiation of Breastfeeding (2 year follow-up); Nothing applied to cord or umbilicus (2 year follow-up); Health worker placed child unclothed on mother's chest/abdomen in skin-to-skin contact (2 year follow-up); First bath delayed by two or more days (2 year follow-up); Breastfed child within one hour of birth (2 year follow-up)
D: In-hospital case-fatality

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Particulate Reduction Education in City Homes (PREACH)
Brief Summary: The purpose of this study is to conduct a randomized controlled trial of the efficacy of a combination of HEPA room air cleaners plus an ETS reduction behavior training as compared to either HEPA air cleaners plus standard asthma education or delayed HEPA air cleaners and standard asthma education (control group).


Options:
A: Rates of clinician delivering cessation assistance other than advice as assessed by parent surveys at baseline and 12 months after clinic visit; Rates of 7-day abstinence as confirmed biochemically at 12 months after clinic visit
B: Presence of a total home smoking ban (Change from baseline in reported total home smoking bans at 3-month and 6-month follow-up)
C: exposure to environmental tobacco smoke (6 months)
D: The primary outcome for this study is reduction in PM10 and PM2.5 over the 6 month follow-up. (6 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Double-blinded Randomized Controlled Trial With Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM) Between 24 and 32 Weeks Gestation
Brief Summary: The purpose of this study is to determine if the short term use of indomethacin will reduce the number of women delivering within 48 hours when given to women with preterm premature rupture of membranes (PPROM) between 24- 32 weeks of gestation. We hypothesize that indomethacin's anti-inflammatory and tocolytic action will reduce the number of women delivering within 48 hours when given to women with PPROM between 24-32 weeks of gestation.


Options:
A: Prolongation of pregnancy (interval from time of randomization to time of delivery) for 48 hours (48 hours)
B: Number of Maternal Participants Who Achieve 48 Hours of Pregnancy Prolongation (48 hours after administration of tocolytic agent)
C: Duration of labor (48 hours)
D: Perinatal morti-morbidity (Up to discharge from hospital, with a maximum of 24 weeks after birth.)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Adapting Web-based Instruction to Learner Baseline Knowledge: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare an adaptive Web-based learning system to a non-adaptive system for teaching physicians-in-training about ambulatory medicine.


Options:
A: Knowledge; Learning efficiency
B: Clinical behaviour on the A&E department, self-efficacy of the nurse in the detection of child abuse and assessment of the individual performance on screening child abuse. (2-3 months)
C: Model of Integrated Capacity Building Program (monthly over 3 years); Competence of individual clinicians (3 observations at pre/post IMID and final); Practice of individual clinicians (Baseline and Endline (9 months)); Clinical performance indicators (Monthly beginning 5 months before OSS)
D: Improvement of drug prescribing (Participants will be followed for the duration of hospital stay, an expected average of 12 days)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Advantages and Disadvantages of Long Term Sedation in ICU Patients
Brief Summary: The purpose of the study is to determine whether sedation of the critical ill patient prolongs the time receiving mechanical ventilation.


Options:
A: delirium outcome (duration of ICU stay(average duration 5 days))
B: Time receiving mechanical ventilation, total intensive care and hospital length of stay.
C: time to successful extubation (This will be the length of time that the patient remains on continuous infusions of sedation and/or analgesia in the ICU. At 60 days, all study interventions will terminate, but patients will be followed for outcomes.)
D: the rate of hematological remission; the rate of molecular remission; the kinetics of the MRD of PML/RARa during and after ATO

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Advantages and Disadvantages of Long Term Sedation in ICU Patients
Brief Summary: The purpose of the study is to determine whether sedation of the critical ill patient prolongs the time receiving mechanical ventilation.


Options:
A: Time receiving mechanical ventilation, total intensive care and hospital length of stay.
B: Hospital mortality (during hospitalization)
C: Number of patients returning to independent functional status: defined as ability to perform 6 activities of daily living (ADL's)(bathing, dressing, eating, grooming, transfer from bed to chair, toileting) and independent ambulation (Hospital Discharge)
D: To determine whether standardized rehabilitation therapy will decrease hospital length of stay. (5 years)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Advantages and Disadvantages of Long Term Sedation in ICU Patients
Brief Summary: The purpose of the study is to determine whether sedation of the critical ill patient prolongs the time receiving mechanical ventilation.


Options:
A: Proportion of time during sedative infusion with a Richmond Agitation Sedation Scale (RASS) score within the individually-prescribed target range; Time from ICU admission to discharge
B: Ventilator free-days (28 days)
C: Time receiving mechanical ventilation, total intensive care and hospital length of stay.
D: Length of mechanical ventilation and ICU stay. Mortality

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Advantages and Disadvantages of Long Term Sedation in ICU Patients
Brief Summary: The purpose of the study is to determine whether sedation of the critical ill patient prolongs the time receiving mechanical ventilation.


Options:
A: Time From Study Drug Initiation to Tracheal Extubation (Duration of ICU stay, for up to 24 weeks)
B: achieving target sedation level (Patients will receive study drug for a maximum of 120 hours (5 days))
C: The percentage of time spent within the protocol specified sedation range (Richmond Agitation-Sedation Scale [RASS] range of -2 to +1) (Preinfusion, Treatment period: every 10min for 30min, 1 & 4 hr after infusion starts, every 4 hrs, prior to end of infusion & extubation. Follow-up Period (48hrs): every 10min for 1st 30min after drug discontinuation, 1, 4, 8,12, 24 & 48 hr post infusion)
D: Time receiving mechanical ventilation, total intensive care and hospital length of stay.

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: COMPAS: A Phase III Study to Demonstrate Efficacy of GSK Biologicals' 10-valent Pneumococcal Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media
Brief Summary: This is a study in a large number of healthy children less than 3 years old to measure the efficacy of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate candidate vaccine (Synflorix vaccine, or GSK1024850A) to prevent cases of pneumonia (lung infection) likely caused by bacteria (Streptococcus pneumoniae and Haemophilus influenzae) or cases of otitis media (ear infection) in children under 3 years old.


Options:
A: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of Life and Assigned to a 3-dose Primary Vaccination Course (Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months)); Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of Life and Assigned to a 2-dose Primary Vaccination Course (Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months))
B: Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP) (Any time from 2 weeks after Dose 3 up to 31 August 2010)
C: Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary Vaccination (At Month 3, one month after the administration of the third dose of pneumococcal conjugate vaccine); Antibody Concentration Against Protein D (PD) - Primary Vaccination (At Month 3, one month after the administration of the third dose of pneumococcal conjugate vaccine)
D: Nasopharyngeal bacterial (pneumococcal) colonization at 6 weeks, 6, 12, 18 and 24 months in infants and at 12 and 24 months of family members (duration of study, 23 months per subject); transmission to family members( sib, caregiver) (at infants age of 12 and 24 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: COMPAS: A Phase III Study to Demonstrate Efficacy of GSK Biologicals' 10-valent Pneumococcal Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media
Brief Summary: This is a study in a large number of healthy children less than 3 years old to measure the efficacy of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate candidate vaccine (Synflorix vaccine, or GSK1024850A) to prevent cases of pneumonia (lung infection) likely caused by bacteria (Streptococcus pneumoniae and Haemophilus influenzae) or cases of otitis media (ear infection) in children under 3 years old.


Options:
A: Nasopharyngeal bacterial (pneumococcal) colonization at 6 weeks, 6, 12, 18 and 24 months in infants and at 12 and 24 months of family members (duration of study, 23 months per subject); transmission to family members( sib, caregiver) (at infants age of 12 and 24 months)
B: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of Life and Assigned to a 3-dose Primary Vaccination Course (Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months)); Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of Life and Assigned to a 2-dose Primary Vaccination Course (Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months))
C: Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary Vaccination (At Month 3, one month after the administration of the third dose of pneumococcal conjugate vaccine); Antibody Concentration Against Protein D (PD) - Primary Vaccination (At Month 3, one month after the administration of the third dose of pneumococcal conjugate vaccine)
D: Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP) (Any time from 2 weeks after Dose 3 up to 31 August 2010)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion
Brief Summary: In this study, we will compare the safety and efficacy of 400 mcg sublingually administered misoprostol alone to standard surgical care for the treatment of incomplete abortion. This study will provide important data on the role of misoprostol in health services offering an array of treatments for incomplete abortion. Women could significantly benefit from a non-invasive treatment option for incomplete abortion. While safe surgical services are becoming more widespread, there is still a serious risk of complications from these procedures. Especially in developing countries, infection, hemorrhage and uterine damage are still too common. Medical treatment of incomplete abortion using misoprostol would be a tremendous step to reducing morbidity and mortality due to abortion complications.


Options:
A: Complete abortion without recourse to surgical intervention. (follow up visit 7 days after initial treatment)
B: Number of surgical evacuation in each group (during de study)
C: Cervical Dilation in Women Following Exposure to Either Ripening Agent (3-4 hours after placement of ripening agent)
D: Percentage of patients with complete abortion (success rate). (1 week)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion
Brief Summary: In this study, we will compare the safety and efficacy of 400 mcg sublingually administered misoprostol alone to standard surgical care for the treatment of incomplete abortion. This study will provide important data on the role of misoprostol in health services offering an array of treatments for incomplete abortion. Women could significantly benefit from a non-invasive treatment option for incomplete abortion. While safe surgical services are becoming more widespread, there is still a serious risk of complications from these procedures. Especially in developing countries, infection, hemorrhage and uterine damage are still too common. Medical treatment of incomplete abortion using misoprostol would be a tremendous step to reducing morbidity and mortality due to abortion complications.


Options:
A: Complete abortion without recourse to surgical intervention. (follow up visit 7 days after initial treatment)
B: Complete abortion (Endometrial thickness of less than 15 mm, as assessed by trans-vaginal ultrasound.) (Day 8 from first misoprostol dose)
C: doxycycline side effects (24 hours)
D: Number of surgical evacuation in each group (during de study)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion
Brief Summary: In this study, we will compare the safety and efficacy of 400 mcg sublingually administered misoprostol alone to standard surgical care for the treatment of incomplete abortion. This study will provide important data on the role of misoprostol in health services offering an array of treatments for incomplete abortion. Women could significantly benefit from a non-invasive treatment option for incomplete abortion. While safe surgical services are becoming more widespread, there is still a serious risk of complications from these procedures. Especially in developing countries, infection, hemorrhage and uterine damage are still too common. Medical treatment of incomplete abortion using misoprostol would be a tremendous step to reducing morbidity and mortality due to abortion complications.


Options:
A: Complete abortion without recourse to surgical intervention. (follow up visit 7 days after initial treatment)
B: complete resolution of signs/symptoms of incomplete abortion without recourse to surgery at any point for any reason (one week after initial treatment)
C: Complete abortion (14 days)
D: Number of surgical evacuation in each group (during de study)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion
Brief Summary: In this study, we will compare the safety and efficacy of 400 mcg sublingually administered misoprostol alone to standard surgical care for the treatment of incomplete abortion. This study will provide important data on the role of misoprostol in health services offering an array of treatments for incomplete abortion. Women could significantly benefit from a non-invasive treatment option for incomplete abortion. While safe surgical services are becoming more widespread, there is still a serious risk of complications from these procedures. Especially in developing countries, infection, hemorrhage and uterine damage are still too common. Medical treatment of incomplete abortion using misoprostol would be a tremendous step to reducing morbidity and mortality due to abortion complications.


Options:
A: doxycycline side effects (24 hours)
B: Number of surgical evacuation in each group (during de study)
C: Complete abortion without recourse to surgical intervention. (follow up visit 7 days after initial treatment)
D: complete resolution of signs/symptoms of incomplete abortion without recourse to surgery at any point for any reason (one week after initial treatment)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney
Brief Summary: This is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (PFS) and evaluate the safety and tolerability of AMG 386 in combination with sorafenib in the treatment of subjects with advanced clear cell carcinoma of the kidney.


Options:
A: Overall survival rate at 12 months (OS12) (landmark) (12 months)
B: Progression-free Survival (PFS) (From randomization until the earliest date of disease progression or date of death from any cause, assessed up to approximately 39 months)
C: Progression Free Survival (PFS) (From randomization date to date of first documented tumor progression or death, whichever occurs first (Up to 31 months))
D: Progression Free Survival (2 3/4 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney
Brief Summary: This is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (PFS) and evaluate the safety and tolerability of AMG 386 in combination with sorafenib in the treatment of subjects with advanced clear cell carcinoma of the kidney.


Options:
A: N/A
B: Progression Free Survival (2 3/4 years)
C: Overall survival (2015 (estimated))
D: Overall Survival (OS) (Baseline up to Month 80)

Answer: B